STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases
Melanoma is a skin cancer which can become metastatic, drug-refractory, and lethal if managed late or inappropriately. An increasing number of melanoma patients exhibits autoimmune diseases, either as pre-existing conditions or as sequelae of immune-based anti-melanoma therapies, which complicate pa...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-09-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/11/10/1448 |
| _version_ | 1797708208827006976 |
|---|---|
| author | Stella Logotheti Brigitte M. Pützer |
| author_facet | Stella Logotheti Brigitte M. Pützer |
| author_sort | Stella Logotheti |
| collection | DOAJ |
| description | Melanoma is a skin cancer which can become metastatic, drug-refractory, and lethal if managed late or inappropriately. An increasing number of melanoma patients exhibits autoimmune diseases, either as pre-existing conditions or as sequelae of immune-based anti-melanoma therapies, which complicate patient management and raise the need for more personalized treatments. STAT3 and/or STAT5 cascades are commonly activated during melanoma progression and mediate the metastatic effects of key oncogenic factors. Deactivation of these cascades enhances antitumor-immune responses, is efficient against metastatic melanoma in the preclinical setting and emerges as a promising targeting strategy, especially for patients resistant to immunotherapies. In the light of the recent realization that cancer and autoimmune diseases share common mechanisms of immune dysregulation, we suggest that the systemic delivery of STAT3 or STAT5 inhibitors could simultaneously target both, melanoma and associated autoimmune diseases, thereby decreasing the overall disease burden and improving quality of life of this patient subpopulation. Herein, we review the recent advances of STAT3 and STAT5 targeting in melanoma, explore which autoimmune diseases are causatively linked to STAT3 and/or STAT5 signaling, and propose that these patients may particularly benefit from treatment with STAT3/STAT5 inhibitors. |
| first_indexed | 2024-03-12T06:19:02Z |
| format | Article |
| id | doaj.art-b27eb2323b374232803bb2e73e23725c |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T06:19:02Z |
| publishDate | 2019-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-b27eb2323b374232803bb2e73e23725c2023-09-03T02:23:07ZengMDPI AGCancers2072-66942019-09-011110144810.3390/cancers11101448cancers11101448STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune DiseasesStella Logotheti0Brigitte M. Pützer1Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, 18057 Rostock, GermanyInstitute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, 18057 Rostock, GermanyMelanoma is a skin cancer which can become metastatic, drug-refractory, and lethal if managed late or inappropriately. An increasing number of melanoma patients exhibits autoimmune diseases, either as pre-existing conditions or as sequelae of immune-based anti-melanoma therapies, which complicate patient management and raise the need for more personalized treatments. STAT3 and/or STAT5 cascades are commonly activated during melanoma progression and mediate the metastatic effects of key oncogenic factors. Deactivation of these cascades enhances antitumor-immune responses, is efficient against metastatic melanoma in the preclinical setting and emerges as a promising targeting strategy, especially for patients resistant to immunotherapies. In the light of the recent realization that cancer and autoimmune diseases share common mechanisms of immune dysregulation, we suggest that the systemic delivery of STAT3 or STAT5 inhibitors could simultaneously target both, melanoma and associated autoimmune diseases, thereby decreasing the overall disease burden and improving quality of life of this patient subpopulation. Herein, we review the recent advances of STAT3 and STAT5 targeting in melanoma, explore which autoimmune diseases are causatively linked to STAT3 and/or STAT5 signaling, and propose that these patients may particularly benefit from treatment with STAT3/STAT5 inhibitors.https://www.mdpi.com/2072-6694/11/10/1448melanomaautoimmune diseaseinflammationstat3stat5immunotherapytumor–immune cell interactions |
| spellingShingle | Stella Logotheti Brigitte M. Pützer STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases Cancers melanoma autoimmune disease inflammation stat3 stat5 immunotherapy tumor–immune cell interactions |
| title | STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases |
| title_full | STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases |
| title_fullStr | STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases |
| title_full_unstemmed | STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases |
| title_short | STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases |
| title_sort | stat3 and stat5 targeting for simultaneous management of melanoma and autoimmune diseases |
| topic | melanoma autoimmune disease inflammation stat3 stat5 immunotherapy tumor–immune cell interactions |
| url | https://www.mdpi.com/2072-6694/11/10/1448 |
| work_keys_str_mv | AT stellalogotheti stat3andstat5targetingforsimultaneousmanagementofmelanomaandautoimmunediseases AT brigittemputzer stat3andstat5targetingforsimultaneousmanagementofmelanomaandautoimmunediseases |